Characterizing the antigenic profile of the human trachea: Implications for tracheal transplantation

Shaari, Christopher M.; Farber, David; Brandwein, Margaret; Gannon, Patrick J.; Urken, Mark L.

doi:10.1002/(sici)1097-0347(199809)20:6<522::aid-hed6>3.0.co;2-o

Cited by 25 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unsurprisingly, the airway mucosa has immunologically active cells playing a key part in airway transplantation, 14 and these contribute to acute allograft rejection, which requires high-dose immunosuppression. 15 Unlike other transplants, airway replace ment is rarely a life-saving procedure, 1 so a completely non-immunogenic tracheal allograft with preserved functional and mechanical characteristics is the minimum target for organ replacement.…”

Section: Discussionmentioning

confidence: 99%

RETRACTED: Clinical transplantation of a tissue-engineered airway

et al. 2008

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

RETRACTED: Clinical transplantation of a tissue-engineered airway

et al. 2008

View full text Add to dashboard Cite

“…Before in vivo assessment of the scaffold the immunogenic properties were verified via MHC‐I immunostaining. Both porcine and human control trachea showed intense staining of the membranes and only mild staining in the cartilaginous part consistent with previous description in the literature (Shaari et al ., ). However, the vacuum decellularized tissue displayed no immunohistochemical staining on the xenoantigen MHC I in contrast to the porcine trachea decellularized under normal atmospheric pressure.…”

Section: Discussionmentioning

confidence: 97%

Pilot study of a novel vacuum-assisted method for decellularization of tracheae for clinical tissue engineering applications

Lange

Greco

Partington³

et al. 2015

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Tissue engineered tracheae have been successfully implanted to treat a small number of patients on compassionate grounds. The treatment has not become mainstream due to the time taken to produce the scaffold and the resultant financial costs. We have developed a method for decellularization (DC) based on vacuum technology, which when combined with an enzyme/detergent protocol significantly reduces the time required to create clinically suitable scaffolds. We have applied this technology to prepare porcine tracheal scaffolds and compared the results to scaffolds produced under normal atmospheric pressures. The principal outcome measures were the reduction in time (9 days to prepare the scaffold) followed by a reduction in residual DNA levels (DC no-vac: 137.8±48.82 ng/mg vs. DC vac 36.83±18.45 ng/mg, p<0.05.). Our approach did not impact on the collagen or glycosaminoglycan content or on the biomechanical properties of the scaffolds. We applied the vacuum technology to human tracheae, which, when implanted in vivo showed no significant adverse immunological response. The addition of a vacuum to a conventional decellularization protocol significantly reduces production time, whilst providing a suitable scaffold. This increases clinical utility and lowers production costs. To our knowledge this is the first time that vacuum assisted decellularization has been explored. Copyright © 2015 John Wiley & Sons, Ltd.

show abstract

“…The most important cell surface molecules involved in tissue or organ rejection are MHC I and II. 27,32,91 Major histocompatibility complex I is expressed on all human cells, whereas MHC II is located on antigen-presenting cells, such as monocytes, which activate a T-cellemediated immune response. 92 In xenograft (animal to humans) transplantation, cell surface antigens from animals that are not expressed in humans, such as the oligosaccharide a-Gal, are introduced, and hyperacute immune responses with a functional failure of the organ or tissue occurs within minutes.…”

Section: Immunogenicitymentioning

confidence: 99%

Whole Organ and Tissue Reconstruction in Thoracic Regenerative Surgery

Lim

Jungebluth

Ajalloueian

et al. 2013

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Development of novel prognostic, diagnostic, and treatment options will provide major benefits for millions of patients with acute or chronic respiratory dysfunction, cardiac-related disorders, esophageal problems, or other diseases in the thorax. Allogeneic organ transplant is currently available. However, it remains a trap because of its dependency on a very limited supply of donated organs, which may be needed for both initial and subsequent transplants. Furthermore, it requires lifelong treatment with immunosuppressants, which are associated with adverse effects. Despite early clinical applications of bioengineered organs and tissues, routine implementation is still far off. For this review, we searched the PubMed, MEDLINE, and Ovid databases for the following keywords for each tissue or organ: tissue engineering, biological and synthetic scaffold/graft, acellular and decelluar(ized), reseeding, bioreactor, tissue replacement, and transplantation. We identified the current state-of-the-art practices in tissue engineering with a focus on advances during the past 5 years. We discuss advantages and disadvantages of biological and synthetic solutions and introduce novel strategies and technologies for the field. The ethical challenges of innovation in this area are also reviewed.

show abstract

Characterizing the antigenic profile of the human trachea: Implications for tracheal transplantation

Cited by 25 publications

References 28 publications

RETRACTED: Clinical transplantation of a tissue-engineered airway

RETRACTED: Clinical transplantation of a tissue-engineered airway

Pilot study of a novel vacuum-assisted method for decellularization of tracheae for clinical tissue engineering applications

Whole Organ and Tissue Reconstruction in Thoracic Regenerative Surgery

Contact Info

Product

Resources

About